The Japan Ministry of Health, Labour and Welfare has approved
GSK's prefilled syringe presentation of Shingrix for the prevention of shingles, according to a statement on Thursday.
The new ready-to-use presentation replaces the previous two-vial format, making administration simpler and more convenient for healthcare professionals.
Shingrix has been approved in Japan since 2018 for adults aged 50 and older and since 2023 for adults aged 18 and older at increased risk of herpes zoster, with approximately 1.1 million people developing shingles in Japan each year.
The prefilled syringe launched in the US in February 2026 and is rolling out across Europe this year.